Canada’s Drug Agency | Drugs, Health Technologies and Systems.

The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19

Details

This report aims to estimate the impacts of providing tocilizumab as a treatment for COVID-19 in Canada on health system costs and health outcomes.

The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population in Canada was infected with COVID-19.
 

Last Updated : March 11, 2025

Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19

Details

Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy and safety of tocilizumab for the treatment of COVID-19. We also characterized which hospitalized patients are most likely to benefit from treatment with tocilizumab.

Last Updated : September 13, 2023